Skip to main content

Table 1 Overview of the literature on the (significant) relation between biomarker and radiographic progression

From: The relation between cartilage biomarkers (C2C, C1,2C, CS846, and CPII) and the long-term outcome of rheumatoid arthritis patients within the CAMERA trial

Author Population No. Biomarker Classification Results
Syversen et al.10 RA ≤4 yr 136 C2C (baseline serum) SHS rapid >1 vs. slow <1 NS
     (radiographic progression per yr, progression change baseline to 5 or 10 yr)  
Mullan et al.9 RA 45 C2C (baseline,1, 3, 6, 9,12-mo serum)   C2C ↑ at 1, 3 mo
  PsA 17 C1,2C SHS rapid >1.5 vs. slow <1.5 C1,2C ↑ at 1, 3 mo
  (mean 11 yr, DAS28 >3.2)   CPII (radiographic progression at 1 yr) NS
    ΔCOL (ΔC2C + ΔC1,2C + ΔCPII)   ΔCOL ↑ at 1, 3, 6, 9 mo
Verstappen et al.11 RA ≤1 yr 87 C2C (1, 2, 3, 4-yr serum)   C2C ↑
    C1,2C 66 th = SHS >7.4 vs. 33 rd percentile = SHS <2.3 C1,2C ↑
    CS846 (radiographic progression over 4-yr span) CS846 ↑
    CPII   NS
Ishiguro et al.7 RA 63 C2C (knee SF) Mild vs. moderate vs. severe RA NS
  (mean 10 yr)   CS846 Mild vs. moderate RA CS846 ↓
    CPII Mild vs. moderate vs. severe RA NS
     (Larsen score: 0, 1 = mild; 2, 3 = moderate; 4, 5 = severe)  
Mansson et al.8 RA ≤2 yr 18 CS846 (baseline serum) Rapid vs. slow hip-joint radiographic progression CS846 ↓
    CPII (Larsen score: rapid = 46; slow = 4 at 2 yr) NS
  1. Number, number of patients investigated in the studies; DAS28, disease activity score based on 28 joints; mo, month; NS, not significant. PsA, psoriatic arthritis; RA, rheumatoid arthritis; SF, synovial fluid; SHS, SharpvanderHeijde score; yr, year.